Skip to main content

Home  About Us  Contact Us  News  Member Login   
Xdynia is a preclinical pharmaceutical company that develops drugs that block Cav3.2 for the prevention and treatment of neuropathic pain. 

Chronic pain  affects 76.2 million Americans with only 40% reporting partial relief of symptoms.  Whether from diabetes, shingles, fibromyalgia, cancer, HIV, trauma, or phantom limb, the Cav3.2 T-channel is a common pathway in its development.

Our library of Cav3.2 inhibitors comes from the minds and labs of the world's experts in Cav3.2.  These compounds are undergoing preclinical studies.